Pharmacological approaches to the prevention of myocardial ischemia-reperfusion injury in experimental study and clinical practice
Why the study?
Reperfusion therapy for myocardial infarction is often complicated by reperfusion injury, prompting interest in whether pharmacological interventions can counteract these harmful effects.
Do pharmacological interventions prevent myocardial ischemia-reperfusion injury in experimental models and clinical practice?
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Reperfusion injury remains a key complication after MI reperfusion; leaves open targeted adjunctive strategies for future trials.
Structured PICO
Do pharmacological interventions prevent myocardial ischemia-reperfusion injury in experimental models and clinical practice?
P
Population
Patients with myocardial infarction undergoing reperfusion therapy and experimental models of myocardial ischemia-reperfusion injury
I
Intervention
Pharmacological interventions including antioxidant flavonols, glucose-insulin-potassium therapy, adenosine, melatonin, phosphocreatine, and cyclosporin A
O
Outcome
Prevention of myocardial ischemia-reperfusion injury (including ventricular arrhythmias, myocardial stunning, micro-vascular dysfunction, and cardiomyocyte death)
Despite promising experimental data, pharmacological therapies to prevent myocardial ischemia-reperfusion injury have not yet demonstrated clinical efficacy.
Cite This Study
Kozhukhov et al. (2019) studied this question.